Japanese Pharma Expects New Deal Model For Next 20 Years - New York Pharma Forum
This article was originally published in PharmAsia News
Executive Summary
NEW YORK - When the New York Pharma Forum, a group consisting primarily of Japanese pharmaceutical executives, gathered for its 20th General Assembly, members reflected on their companies' early days in the U.S. and their prospects for the future, when the scope of partnerships between Western pharma and Asia Pacific pharma will begin to change
You may also be interested in...
The Rise Of Japanese Pharma Dealmakers
Japanese pharmas are now serious contenders for partnerships outside their home country, increasing their spending on both alliances and acquisitions in recent years. The increased desire to partner with Western biotechs is good news for smaller industry players as the recent spate of mega-mergers has resulted in a smaller pool of potential acquirers for their assets.IN VIVO presents an analysis of recent trends in biopharmaceutical dealmaking between Japan and the West.
The Rise Of Japanese Pharma Dealmakers
Japanese pharmas are now serious contenders for partnerships outside their home country, increasing their spending on both alliances and acquisitions in recent years. The increased desire to partner with Western biotechs is good news for smaller industry players as the recent spate of mega-mergers has resulted in a smaller pool of potential acquirers for their assets.IN VIVO presents an analysis of recent trends in biopharmaceutical dealmaking between Japan and the West.
M&A In India May Lose Steam As Potential Sellers Raise Their Price Tags, Investment Bankers Say
MUMBAI - Greed is getting in the way of several prospective mergers and acquisitions in the Indian pharmaceutical industry, two senior investment bankers told PharmAsia News, but reiterated that multinational companies are still keenly scanning companies that fit into their global programs